Testosterone: A metabolic hormone in health and disease

Journal of Endocrinology

Volumn 217, Issue 3, 2013, Pages

  Kelly, Daniel M ^a   Jones, T Hugh ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Metabolic syndrome; Metabolism; Testosterone; Type 2 diabetes

Indexed keywords

CHOLESTEROL; GLYCOGEN; LIPID; PLACEBO; TESTOSTERONE; TESTOSTERONE ESTER; TRIACYLGLYCEROL;

ANDROGEN DEFICIENCY; BODY MASS; CARBOHYDRATE METABOLISM; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; MOLECULAR MECHANICS; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVIEW;

BLOOD GLUCOSE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; TESTOSTERONE;

EID: 84878801588     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0455     Document Type: Review

References (199)

1. Abate N, Haffner SM, Garg A, Peshock RM& Grundy SM2002 Sex steroid hormones, upper body obesity, and insulin resistance. Journal of Clinical Endocrinology andMetabolism874522-4527. (doi:10.1210/jc.2002-020567)
2. Agledahl I,Hansen JB&Svartberg J 2008 Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scandinavian Journal of Clinical and Laboratory Investigation 68 641-648. (doi:10.1080/00365510801999068)
3. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE & White MF 2002 Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. Journal of Biological Chemistry 277 1531-1537. (doi:10.1074/ jbc.M101521200)
4. Allan CA, Strauss BJ, Burger HG, Forbes EA & McLachlan RI 2008 Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. Journal of Clinical Endocrinology and Metabolism 93 139-146. (doi:10.1210/jc.2007-1291)
5. Apostolakis M, Matzelt D & Voigt KD 1963 The effect of testosterone propionate on glycolytic and transamination enzyme activities in the liver, biceps muscle and levator ani muscle in rats. Biochemische Zeitschrift 337 414-424.
6. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT & Wittert GA 2011 Clinical review: endogenous testosterone and mortality in men: asystematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 96 3007-3090. (doi:10.1210/jc.2011-1137)
7. Arner P 2005 Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Practice & Research. Clinical Endocrinology & Metabolism 19 471-482. (doi:10.1016/j.beem.2005.07.004)
8. Aversa A, Bruzziches R, Francomano D, Spera G & Lenzi A 2010b Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation 33 776-783.
9. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE & Bremner WJ 1994 Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. Journal of Clinical Endocrinology and Metabolism 79 561-567. (doi:10.1210/jc.79.2.561)
10. Barrett-Connor E 1992 Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Annals of Internal Medicine 117 807-811.
11. Barrett-Connor E & Khaw KT 1988 Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78 539-545. (doi:10.1161/01.CIR.78.3.539)
12. Barud W, Palusiński R, Beltowski J & Wójcicka G 2002 Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis 164 283-288. (doi:10.1016/S0021-9150(02)00069-2)
13. Basu R, Dalla Man C, Campioni M, Basu A, Nair KS, Jensen MD, Khosla S, Klee G, Toffolo G, Cobelli C et al. 2007 Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 30 1972-9078. (doi:10.2337/dc07-0359)
14. Bergamini E 1975 Different mechanisms in testosterone action on glycogen metabolism in rat perineal and skeletal muscles. Endocrinology 96 77-84. (doi:10.1210/endo-96-1-77)
15. Bergamini E, Bombara G & Pellegrino C 1968 The effect of testosterone on glycogen metabolism in rat levator ani muscle. Biochimica et Biophysica Acta 177 220-234. (doi:10.1016/0304-4165(69)90131-7)
16. Birzniece V, Meinhardt UJ, Handelsman DJ & Ho KK 2009 Testosterone stimulates extra-hepatic but not hepatic fat oxidation (Fox): comparison of oral and transdermal testosterone administration in hypopituitary men. Clinical Endocrinology 71 715-721. (doi:10.1111/j.1365-2265. 2009.03524.x)
17. Boyanov M, Boneva Z & Christov V 2003 Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6 1-7.
18. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS & Basaria S 2006 Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. International Journal of Impotence Research 18 494-498. (doi:10.1038/sj.ijir.3901471)
19. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH & van der Schouw YT 2010 Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. International Journal of Epidemiology 40 189-207. (doi:10.1093/ije/dyq158)
20. Brown MS & Goldstein JL 1999 A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. PNAS 96 11041-11048. (doi:10.1073/pnas.96.20.11041)
21. Bryant NJ, Govers R & James DE 2002 Regulated transport of the glucose transporter GLUT4. Nature Reviews. Molecular Cell Biology 3 267-277. (doi:10.1038/nrm782)
22. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M & Rosano GM 2009 Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. Journal of the American College of Cardiology 54 990-927. (doi:10.1016/j.jacc.2009.04.078)
23. Chen X, Li X, Huang HY, Li X & Lin JF 2006 Effects of testosterone on insulin receptor substrate-1 and glucose transporter 4 expression in cells sensitive to insulin. Zhonghua Yi Xue Za Zhi 86 1474-1477.
24. Chow JD, Jones ME, Prelle K, Simpson ER & Boon WC 2011 A selective estrogen receptor a agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. Journal of Endocrinology 210 323-334. (doi:10.1530/JOE-10-0462)
25. Cohen P 1999 The hypogonadal-obesity cycle. Medical Hypotheses 52 49-51. (doi:10.1054/mehy.9097.0624)
26. Corona G, Mannucci E, Schulman C, Petrone L, Mansani R, Cilotti A, Balercia G, Chiarini V, Forti G & Maggi M 2006 Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. European Urology 50 595-604. (doi:10.1016/j.eururo. 2006.02.053)
27. Corona G, Mannucci E, Forti G & Maggi M 2009 Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. International Journal of Andrology 32 587-598. (doi:10.1111/j.1365-2605.2008.00951.x)
28. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E & Maggi M 2011 Testosterone and metabolic syndrome: a meta-analysis study. Journal of Sexual Medicine 8 272-283. (doi:10.1111/j.1743-6109.2010.09091.x)
29. Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Després JP & Bouchard C 2000 Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. Journal of Clinical Endocrinology and Metabolism 85 1026-1031. (doi:10.1210/jc.85.3.1026)
30. Denti L, PasoliniG, Sanfelici L, Benedetti R, Cecchetti A, Ceda GP, Ablondi F & Valenti G 2000 Aging-related decline of gonadal function in healthy men: correlation with body composition and lipoproteins. Journal of the American Geriatrics Society 48 51-58.
31. De Pergola G 2000 The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. International Journal of Obesity and Related Metabolic Disorders 24(Suppl 2) S59-S63. (doi:10.1038/sj.ijo.0801280)
32. Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, Kitabchi AE & Wake RW 2007 Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU International 100 1060-1065.
33. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A & Dandona P 2004 Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89 5462-5468. (doi:10.1210/jc.2004-0804)
34. Dhindsa S, Bhatia V, Dhindsa G, Chaudhuri A, Gollapudi GM & Dandona P 2007 The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 30 1860-1861. (doi:10.2337/dc07-0337)
35. Diaz-Arjonilla M, Schwarcz M, Swerdloff RS & Wang C 2009 Obesity, low testosterone levels and erectile dysfunction. International Journal of Impotence Research 21 89-98. (doi:10.1038/ijir.2008.42)
36. Dicker A, Rydén M, Näslund E, Muehlen IE, Wirén M, Lafontan M & Arner P 2004 Effect of testosterone on lipolysis in human preadipocytes from different fat depots. Diabetologia 47 420-428. (doi:10.1007/s00125-003-1324-0)
37. Ding EL, Song Y, Malik VS & Liu S 2006 Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and metaanalysis. Journal of the American Medical Association 295 1288-1299. (doi:10.1001/jama.295.11.1288)
38. Dobrzyn P, Jazurek M & Dobrzyn A 2010 Stearoyl-CoA desaturase and insulin signaling - what is the molecular switch?. Biochimica et Biophysica Acta 1797 1189-1904. (doi:10.1016/j.bbabio.2010.02.007)
39. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M & Rajkumar C 2003 Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science 104 195-201. (doi:10.1042/CS20020209)
40. Du J, Zhang L & Wang Z 2009 Testosterone inhibits the activity of peroxisome proliferator-activated receptor g in a transcriptional transaction assay. Die Pharmazie 64 692-693.
41. Eckel RH 1989 Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. New England Journal of Medicine 320 1060-1068. (doi:10.1056/NEJM908904203201607)
42. Faris JE & Smith MR 2010 Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Current Opinion in Endocrinology, Diabetes, and Obesity 17 240-246. (doi:10.1097/MED. 0b013e3283391fd1)
43. Finn PD, Cunningham MJ, Pau KY, Spies HG, Clifton DK & Steiner RA 1998 The stimulatory effect of leptin on the neuroendocrine reproductive axis of the monkey. Endocrinology 139 4652-4662. (doi:10.1210/ en.139.11.4652)
44. Frederiksen L, Højlund K, Hougaard DM, Brixen K & Andersen M 2012a Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age 34 145-156. (doi:10.1007/s11357-011-9213-9)
45. Frederiksen L, Højlund K, HougaardDM,Mosbech TH, Larsen R, Flyvbjerg A, Frystyk J, Brixen K & AndersenM2012b Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. European Journal of Endocrinology 166 469-476. (doi:10.1530/EJE-11-0565)
46. Garaulet M, Pérex-Llamas F, Fuente T, Zamora S & Tebar FJ 2000 Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-a, sex hormone-binding globulin and sex hormones. European Journal of Endocrinology 143 657-666. (doi:10.1530/eje.0.1430657)
47. García-Arencibia M, Dávila N, Campión J, Carmen Carranza M & Calle C 2005 Identification of two functional estrogen response elements complexed with AP-1-like sites in the human insulin receptor gene promoter. Journal of Steroid Biochemistry and Molecular Biology 94 1-14. (doi:10.1016/j.jsbmb.2004.12.020)
48. George JT, Millar RP & Anderson RA 2010 Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. Neuroendocrinology 91 302-307. (doi:10.1159/000299767)
49. Gibney J, Wolthers T, Johannsson G, Umpleby AM & Ho KK 2005 Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. American Journal of Physiology. Endocrinology and Metabolism 289 E266-E271. (doi:10.1152/ ajpendo.00483.2004)
50. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U et al. 2006 Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New England Journal of Medicine 354 2552-2563. (doi:10.1056/ NEJMoa054862)
51. Grossmann M, Gianatti EJ & Zajac JD 2010 Testosterone and type 2 diabetes. Current Opinion in Endocrinology, Diabetes, and Obesity 17 247-256. (doi:10.1097/MED.0b013e32833990cf)
52. Gruen R, Hietanen E & Greenwood MR 1978 Increased adipose tissue lipoprotein lipase activity during the development of the genetically obese rat (fa/fa). Metabolism 12(Suppl 2) 1955-9066. (doi:10.1016/ S0026-0495(78)80012-2)
53. Guzik TJ, Mangalat D & Korbut R 2006 Adipocytokines: novel link between inflammation and vascular function? Journal of Physiology and Pharmacology 57 505-528.
54. Haffner S, Mykkanen L, Valdez R & Katz M 1993 Relationship of sex hormones to lipids and lipoproteins in non-diabetic men. Journal of Clinical Endocrinology and Metabolism 77 1610-1615. (doi:10.1210/ jc.77.6.1610)
55. Haffner SM, Shaten J, Stern MP, Smith GD & Kuller L 1996 Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. American Journal of Epidemiology 143 889-897. (doi:10.1093/oxfordjournals.aje.a008832)
56. Haider A, Yassin A, Saad F & Shabsigh R 2007 Effect of androgen deprivation on glycaemic control and on cardiovascular risk factors in men with advanced prostate cancer with diabetes. Aging Male 10 189-906. (doi:10.1080/13685530701653538)
57. Hall DW, Van den Hoven WE, Noordzij-Kamermans NJ & Jaitly KD 1983 Hormonal control of hamster ear sebaceous gland lipogenesis. Archives of Dermatological Research 275 1-7. (doi:10.1007/BF00516546)
58. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD & Grossmann M 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clinical Endocrinology 74 377-383. (doi:10.1111/ j.1365-2265.2010.03942.x)
59. Hansen FM, Fahmy N & Nielsen JH 1980 The influence of sexual hormones on lipogenesis and lipolysis in rat fat cells. Acta Endocrinologica 95 566-570.
60. Haring R,VölzkeH, Felix SB, Schipf S, DorrM, Rosskopf D, NauckM, SchoflC &WallaschofskiH2009 Prediction ofmetabolic syndrome by low serum testosterone levels in men. Results from the study of health in Pomerania. Diabetes Care 58 2027-2031. (doi:10.2337/db09-0031)
61. Hayes FJ, Seminara SB, Decruz S, Boepple PA & Crowley WF Jr 2000 Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. Journal of Clinical Endocrinology and Metabolism 85 3027-3035. (doi:10.1210/jc.85.9.3027)
62. Hayes FJ, DeCruz S, Seminara SB, Boepple PA & Crowley WF Jr 2001 Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. Journal of Clinical Endocrinology and Metabolism 86 53-58. (doi:10.1210/jc.86.1.53)
63. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G & Swinnen JV 2001 Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Molecular Endocrinology 15 1817-1828. (doi:10.1210/me.15.10.1817)
64. Heemers H, Verrijdt G, Organe S, Claessens F, Heyns W, Verhoeven G & Swinnen JV 2004 Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavageactivating protein gene allowing direct regulation by the androgen receptor. Journal of Biological Chemistry 279 30880-30887. (doi:10.1074/jbc.M401615200)
65. Heufelder AE, Saad F, Bunck MC & Gooren L 2009 Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. Journal of Andrology 30 726-733. (doi:10.2164/jandrol.108.007005)
66. Huang WC, Li X, Liu J, Lin J & Chung LW 2012 Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Molecular Cancer Research 10 133-142. (doi:10.1158/1541-7786. MCR-11-0206)
67. Isidori AM, Caprio M, Stroll F, Moretti C, Frajese G, Isidori A & Fabbri A 1999 Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. Journal of Clinical Endocrinology and Metabolism 84 3673-3680. (doi:10.1210/jc.84.10.3673)
68. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A & Fabbri A 2005 Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a metaanalysis. Clinical Endocrinology 63 280-293. (doi:10.1111/j.1365-2265. 2005.02339.x)
69. Itani SI, Ruderman NB, Schmieder F & Boden G 2002 Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB-a. Diabetes 51 2005-2011. (doi:10.2337/diabetes.51.7.2005)
70. James RW, Brulhart-Meynet MC, Lehmann T & Golay A 1997 Lipoprotein distribution and composition in obesity: their association with central adiposity. International Journal of Obesity and Related Metabolic Disorders 21 1115-1120. (doi:10.1038/sj.ijo.0800524)
71. Jones TH 2007 Testosterone associations with erectile dysfunction, diabetes and the metabolic syndrome. European Urology Supplements 6 847-857. (doi:10.1016/j.eursup.2007.07.002)
72. Jones TH 2010a Testosterone deficiency: a risk factor for cardiovascular disease?. Trends in Endocrinology and Metabolism 21 496-503. (doi:10.1016/j.tem.2010.03.002)
73. Jones TH 2010b Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. Journal of Diabetes 2 146-156. (doi:10.1111/ j.1753-0407.2010.00085.x)
74. Jones TH 2011 Cardiovascular risk during androgen deprivation therapy for prostate cancer. BMJ 342 d3105. (doi:10.1136/bmj.d3105)
75. Jones TH & Saad F 2009 The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 207 318-327. (doi:10.1016/j.atherosclerosis.2009.04.016)
76. Jones TH, Arver S, Behre HM, Buvat J,Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD et al. 2011 Testosterone replacement in hypogonadal menwith type 2 diabetes and/ormetabolic syndrome (the TIMES2 study). Diabetes Care 34 828-837. (doi:10.2337/ dc10-1233)
77. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ & Saad F 2010 Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clinical Endocrinology 73 602-612. (doi:10.1111/j.1365-2265. 2010.03845.x)
78. Kapoor D, Malkin CJ, Channer KS & Jones TH 2005 Androgens, insulin resistance and vascular disease in men. Clinical Endocrinology 63 239-250. (doi:10.1111/j.1365-2265.2005.02299.x)
79. Kapoor D, Goodwin E, Channer KS & Jones TH 2006 Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 154 899-906. (doi:10.1530/eje.1.02166)
80. Kapoor D, Aldred H, Clark S, Channer KS & Jones TH 2007a Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30 911-917. (doi:10.2337/dc06-1426)
81. Kapoor D, Clark S, Stanworth R, Channer KS & Jones TH 2007b The effects of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 156 595-602. (doi:10.1530/EJE-06-0737)
82. Keating NL, O'Malley AJ & Smith MR 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 24 4448-4456. (doi:10.1200/JCO.2006. 06.2497)
83. Kelley DE & Mandarino LJ 2000 Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49 677-683. (doi:10.2337/ diabetes.49.5.677)
84. Kelly DM, Akhtar S, Brooke JC, Muraleedharan V, Channer KS & Jones TH 2012 Testosterone increases hepatic liver X receptor and ApoE expression and improves lipid metabolism in the testicular feminized mouse: a potential protective mechanism against atherosclerosis and fatty liver disease. Endocrine Reviews 33 OR22-OR25.
85. Kahn SE, Hull RL & Utzschneider KM 2006 Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444 840-846. (doi:10.1038/nature05482)
86. Khaw KT, DowsettM, Folkerd E, Bingham S, Wareham N, Luben R,Welch A & Day N 2007 Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116 2694-2701. (doi:10.1161/CIRCULATIONAHA. 107.790005)
87. Kiel DP, Baron JA, Plymate SR & Chute CG 1989 Sex hormones and lipoproteins in men. American Journal of Medicine 87 35-39. (doi:10.1016/S0002-9343(89)80480-2)
88. Kley HK, Nieschlag E,WiegelmannW, Solbach HG & Krüskemper HL 1975 Steroid hormones and their binding in plasma of male patients with fatty liver, chronic hepatitis and liver cirrhosis. Acta Endocrinologica 79 275-285.
89. Knudsen J, Jensen MV, Hansen JK, Faergeman NJ, Neergaard TB & Gaigg B 1999 Role of acyl-CoA binding protein in acyl-CoA transport, metabolism and cell signaling. Molecular and Cellular Biochemistry 192 95-103. (doi:10.1023/A:1006830606060)
90. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC et al. 2003 Inflammatory markers, adiponectin and the risk of type 2 diabetes in the Pima Indians. Diabetes Care 26 1745-1751. (doi:10.2337/diacare. 26.6.1745)
91. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ & McKinlay JB 2006 Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in non-obese men. Journal of Clinical Endocrinology and Metabolism 91 843-850. (doi:10.1210/jc.2005-1326)
92. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R & Salonen JT 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27 1036-1041. (doi:10.2337/diacare.27.5.1036)
93. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP & Salonen JT 2005 The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. Journal of Clinical Endocrinology and Metabolism 19 712-790. (doi:10.1210/jc.2004-0970)
94. Lanfranco F, Zitzmann M, Simoni M & Nieschlag E 2004 Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clinical Endocrinology 60 500-507. (doi:10.1111/ j.1365-2265.2004.02007.x)
95. Leonard SL 1952 The effect of castration and testosterone propionate injection on glycogen storage in skeletal muscle. Endocrinology 51 293-297. (doi:10.1210/endo-51-4-293)
96. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR & Zakai N 2010 Androgen deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121 833-840. (doi:10.1161/CIRCULATIONAHA.109.902695)
97. Lim S, Son KR, Song IC, Park HS, Jin CJ, Jang HC, Park KS, Kim YB & Lee HK 2008 Fat in liver/muscle correlates more strongly with insulin sensitivity in rats than abdominal fat. Obesity 17 188-905. (doi:10.1038/oby.2008.486)
98. Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD et al. 2008 Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 47 1924-9035. (doi:10.1002/hep.22252)
99. Macotela Y, Boucher J, Tran TT & Kahn CR 2009 Sex and depot differences in adipocyte insulin sensitivity and glucose metabolism. Diabetes 58 803-812. (doi:10.2337/db08-1054)
100. Maggio M, Basaria S, Ble A, Lauretani F, Bandinelli S, Ceda GP, Valenti G, Ling SM & Ferrucci L 2006 Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. Journal of Clinical Endocrinology and Metabolism 91 345-347. (doi:10.1210/jc.2005-1097)
101. Makhsida N, Shah J, Yan G, Fisch H & Shabsigh R 2005 Hypogonadism and metabolic syndrome: implications for testosterone therapy. Journal of Urology 174 827-834. (doi:10.1097/01.ju.0000169490.78443.59)
102. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH & Channer KS 2004a Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 19 871-876. (doi:10.1136/hrt.2003.021121)
103. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS & Jones TH 2004b The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 89 3313-3318. (doi:10.1210/jc.2003- 031069)
104. Malkin CJ, Jones TH & Channer KS 2007 The effect of testosterone on insulin sensitivity in men with heart failure. European Journal of Heart Failure 9 44-50. (doi:10.1016/j.ejheart.2006.04.006)
105. Mantzoros CS 1999 The role of leptin in human obesity and disease: a review of current evidence. Annals of Internal Medicine 130 671-680. Mårin P & Arver S 1998 Androgens and abdominal obesity. Baillière's Clinical Endocrinology and Metabolism 12 441-451. (doi:10.1016/S0950- 351X(98)80901-2)
106. Mårin P, Krotkiewski M & Bjorntorp P 1992a Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. European Journal of Medicine 1 329-336.
107. Mårin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G & Bjorntorp P 1992b The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity and Related Metabolic Disorders 16 991-997.
108. Mårin P, Odén B & Björntorp P 1995 Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. Journal of Clinical Endocrinology and Metabolism 80 239-243. (doi:10.1210/jc.80.1.239)
109. Mårin P, Lönn L, Andersson B, Odén B, Olbe L, Bengtsson BA & Björntorp P 1996 Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. Journal of Clinical Endocrinology and Metabolism 81 1018-1022. (doi:10.1210/jc.81.3.1018)
110. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD & Urban RJ 1998 Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. Journal of Clinical Endocrinology and Metabolism 83 1886-1892. (doi:10.1210/jc.83.6.1886)
111. Max SR 1984 Androgen-estrogen synergy in rat levator ani muscle: glucose- 6-phosphate dehydrogenase. Molecular and Cellular Endocrinology 38 103-107. (doi:10.1016/0303-7207(84)90108-4)
112. Max SR & Knudsen JF 1980 Effect of sex hormones on glucose-6-phosphate dehydrogenase in rat levator ani muscle. Molecular and Cellular Endocrinology 17 111-118. (doi:10.1016/0303-7207(80)90123-9)
113. McInnes KJ, Smith LB, Hunger NI, Saunders PT, Andrew R & Walker BR 2012 Deletion of the androgen receptor in adipose tissue in male mice elevates retinol binding protein 4 and reveals independent effects on visceral fat mass and on glucose homeostasis. Diabetes 61 1072-1081. (doi:10.2337/db11-1136)
114. McLaren D, Kelly D, Akhtar S, Channer K & Jones T 2012 Low testosterone is associated with decreased expression of glut-4 and hexokinase 2 in muscle of the testicular feminised mouse. Endocrine Abstracts 29 P559.
115. Morris PD & Channer KS 2012 Testosterone and cardiovascular disease in men. Asian Journal of Andrology 14 428-435. (doi:10.1038/aja.2012.21)
116. Moulana M, Lima R & Reckelhoff JF 2011 Metabolic syndrome, androgens, and hypertension. Current Hypertension Reports 13 158-162. (doi:10.1007/s19006-011-0184-0)
117. Movérare-Skrtic S, Venken K, Andersson N, Lindberg MK, Svensson J, Swanson C, Vanderschueren D, Oscarsson J, Gustafsson JA & Ohlsson C 2006 Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity 14 662-672. (doi:10.1038/oby.2006.75)
118. Muraleedharan V & Jones TH 2010 Testosterone and the metabolic syndrome. Therapeutic Advances in Endocrinology and Metabolism 1 207-223. (doi:10.1177/2042018810390258)
119. Muraleedharan V, Marsh H, Channer KS & Jones TH 2011 Long-term testosterone replacement improves survival in men with type 2 diabetes and hypogonadism. Endocrine Reviews 32 (03_Meeting Abstracts) OR35-2.
120. Muthusamy T, Murugesan P & Balasubramanian K 2009 Sex steroids deficiency impairs glucose transporter 4 expression and its translocation through defective Akt phosphorylation in target tissues of adult male rat. Metabolism 58 1581-1592. (doi:10.1016/j.metabol.2009.05.010)
121. Muthusamy T, Murugesan P, Srinivasan C & Balasubramanian K 2011 Sex steroids influence glucose oxidation through modulation of insulin receptor expression and IRS-1 serine phosphorylation in target tissues of adult male rat. Molecular and Cellular Biochemistry 352 35-45. (doi:10.1007/s11010-011-0737-1)
122. Myking O, Aakvaag A & Digranes O 1987 Androgen-oestrogen imbalance in men with chronic alcoholism and fatty liver. Alcohol and Alcoholism 22 7-15.
123. Nettleship JE, Pugh PJ, Channer KS, Jones T & Jones RD 2007 Inverse relationship between serum levels of interleukin-1b and testosterone in men with stable coronary artery disease. Hormone and Metabolic Research 39 366-371. (doi:10.1055/s-2007-976543)
124. Nielsen TL, Hagen C, Wraae K, Brixen K, Petersen PH, Haug E, Larsen R & Andersen M 2007 Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. Journal of Clinical Endocrinology and Metabolism 92 2696-2705. (doi:10.1210/jc.2006-1847)
125. Nishiyama T, Ishizaki F, Anraku T, Shimura H & Takahashi K 2005 The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. Journal of Clinical Endocrinology and Metabolism 19 657-660. (doi:10.1210/jc.2004-1611)
126. Oh J, Barrett-Connor E, Wedick N & Wingard D 2002 Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care 25 55-60. (doi:10.2337/diacare.25.1.55)
127. Olorunshola KV, Aliyu OF & Achie LN 2012 Testosterone and orchidectomy modulates intestinal fluid and glucose transport in Albino Wistar rat. European Journal of Scientific Research 76 281-287.
128. Ost A, Danielsson A, Lidén M, Eriksson U, Nystrom FH & Strålfors P 2007 Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB Journal 21 3696-3704. (doi:10.1096/fj.07-8173com)
129. Page ST, Herbst KL, Amory JK, Coviello AD, Anawalt BD, Matsumoto AM & Bremner WJ 2005 Testosterone administration suppresses adiponectin levels in men. Journal of Andrology 26 85-92.
130. Parthasarathy C, Renuka VN & Balasubramanian K 2009 Sex steroids enhance insulin receptors and glucose oxidation in Chang liver cells. Clinica Chimica Acta 399 49-53. (doi:10.1016/j.cca.2008.09.011)
131. Pecquery R, Leneveu MC & Giudicelli Y 1988 Influence of androgenic status on the a2/b-adrenergic control of lipolysis in white fat cells: predominant a2-antilipolytic response in testosterone-treatedcastrated hamsters. Endocrinology 122 2590-2596. (doi:10.1210/ endo-122-6-2590)
132. Pessin JE & Saltiel AR 2000 Signaling pathways in insulin action: molecular targets of insulin resistance. Journal of Clinical Investigation 106 165-169. (doi:10.1172/JCI10582)
133. Phillips G 1993 Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism 42 116-120. (doi:10.1016/0026-0495(93)90181-M)
134. Pitteloud N, HardinM, Dwyer AA, Valassi E, YialamasM, Elahi D & Hayes FJ 2005a Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. Journal of Clinical Endocrinology and Metabolism 19 2636-2641. (doi:10.1210/jc.2004-2900)
135. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D et al. 2005b Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28 1636-1642. (doi:10.2337/diacare. 28.7.1636)
136. Ramamani A, Aruldhas MM & Govindarajulu P 1999 Differential response of rat skeletal muscle glycogen metabolism to testosterone and estradiol. Canadian Journal of Physiology and Pharmacology 77 300-304. (doi:10.1139/y99-016)
137. Ramirez ME, McMurry MP, Wiebke GA, Felten KJ, Ren K, Meikle AW & Iverius PH 1997 Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. Metabolism 46 179-185. (doi:10.1016/S0026-0495(97)90299-7)
138. Rebuffé-Scrive M, Mårin P & Björntorp P 1991 Effect of testosterone on abdominal adipose tissue in men. International Journal of Obesity 15 791-795.
139. Reis C, Liberman S, Pompeo AC, Srougi M, Halpern A & Jacob FilhoW2009 Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy. Clinics 64 781-784. (doi:10.1590/S1807-59322009000800012)
140. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR & Andres R 2007 Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. Journal of Clinical Endocrinology and Metabolism 92 3568-3572. (doi:10.1210/jc.2006-2764)
141. Roseweir AK & Millar RP 2009 The role of kisspeptin in the control of gonadotrophin secretion. Human Reproduction Update 15 203-212. (doi:10.1093/humupd/dmn058)
142. Rosignoli C, Nicolas JC, Jomard A & Michel S 2003 Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. Experimental Dermatology 12 480-489. (doi:10.1034/j.1600- 0625.2003.00014.x)
143. Saad F, Gooren L, Haider A & Yassin A 2007 An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Archives of Andrology 53 353-357. (doi:10.1080/ 01485010701730880)
144. Saad F, Gooren LJ, Haider A & Yassin A 2008 A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. Journal of Andrology 29 102-105. (doi:10.2164/jandrol.107. 002774)
145. Saad F, Aversa A, Isidori AM & Gooren LJ 2012 Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Current Diabetes Reports 8 131-143. (doi:10.2174/ 157339912799424573)
146. Salam R, Kshetrimayum AS & Keisam R 2012 Testosterone and metabolic syndrome: the link. Indian Journal of Endocrinology and Metabolism 16(Suppl 1) S12-S90. (doi:10.4103/2230-8210.94248)
147. Salehzadeh F, Rune A, Osler M & Al-Khalili L 2011 Testosterone or 17b-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. Journal of Endocrinology 210 290-229. (doi:10.1530/JOE-10-0497)
148. Sansone G, DavidsonW, Cummings B & Reisner RM 1971 Sebaceous gland lipogenesis induced by testosterone: early metabolic events. Journal of Investigative Dermatology 57 144-148. (doi:10.1111/1523-1747. ep12261491)
149. Santosa S & Jensen MD 2012 Effects of male hypogonadism on regional adipose tissue fatty acid storage and lipogenic proteins. PLoS ONE 7 e31473. (doi:10.1371/journal.pone.0031473)
150. Sato K, Iemitsu M, Aizawa K & Ajisaka R 2008 Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism 294 E961-E968. (doi:10.1152/ajpendo.00678.2007)
151. Schuster DP 2010 Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 3 253-262. (doi:10.2147/DMSOTT.S7354)
152. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H & Sannerstedt R 1990 Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39 897-901. (doi:10.1016/0026-0495(90)90297-P)
153. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH & Platz EA 2007 Androgens and diabetes in men. Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30 234-238. (doi:10.2337/ dc06-1579)
154. Sesti G, Marini MA, Briata P, Tullio AN, Montemurro A, Borboni P, De Pirro R, Gherzi R & Lauro R 1992 Androgens increase insulin receptor mRNA levels, insulin binding, and insulin responsiveness in HEp-2 larynx carcinoma cells. Molecular and Cellular Endocrinology 86 111-118. (doi:10.1016/0303-7207(92)90181-5)
155. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L, Heufelder A, Jones H, Meryn S & Zitzmann M 2008 The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. International Journal of Clinical Practice 62 791-798. (doi:10.1111/j.1742-1241.2008.01696.x)
156. Shahani S, Braga-BasariaM& Basaria S 2008 Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Journal of Clinical Endocrinology and Metabolism 93 2042-2049. (doi:10.1210/ jc.2007-2595)
157. Shoelson SE, Lee J & Goldfine AB 2006 Inflammation and insulin resistance. Journal of Clinical Investigation 116 1793-1801. (doi:10.1172/ JCI29069)
158. Shores MM, Smith NL, Forsberg CW, Anawalt BD & Matsumoto AM 2012 Testosterone treatment and mortality in men with low testosterone levels. Journal of Clinical Endocrinology and Metabolism 97 2050-2058. (doi:10.1210/jc.2011-2591)
159. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L & Eschwege E 1997 Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. Journal of Clinical Endocrinology and Metabolism 82 682-685. (doi:10.1210/jc.82.2.682)
160. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N & Bhasin S 2002 The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Journal of Clinical Endocrinology and Metabolism 87 136-143. (doi:10.1210/jc.87.1.136)
161. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF & Davies JS 2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Clinical Endocrinology and Metabolism 86 4261-4267. (doi:10.1210/jc.86.9.4261)
162. SmithMR, Finkelstein JS,McGovernFJ, ZietmanAL, FallonMA, ShoenfeldDA & Kantoff PW 2002 Changes in body composition during androgen deprivation therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism 87 599-603. (doi:10.1210/jc.87.2.599)
163. Smith MR, Lee H & Nathan DM 2006 Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism 91 1305-1308. (doi:10.1210/jc.2005-2507)
164. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H & Pfeiffer AF 2003 Adiponectin and protection against type 2 diabetes. Lancet 361 226-228. (doi:10.1016/S0140-6736(03)12255-6)
165. Srikanthan P & Karlamangla AS 2011 Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the Third National Health and Nutrition Examination Survey. Journal of Clinical Endocrinology and Metabolism 96 2898-2903. (doi:10.1210/ jc.2011-0435)
166. Stanworth RD & Jones TH 2009 Testosterone in obesity, metabolic syndrome and type 2 diabetes. Frontiers of Hormone Research 37 74-90.
167. Stanworth RD, Kapoor D, Channer KS & Jones TH 2008 Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. European Journal of Endocrinology 159 736-746. (doi:10.1530/EJE-08-0266)
168. Stanworth RD, Kapoor D, Channer KS & Jones TH 2011 Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clinical Endocrinology 74 624-630. (doi:10.1111/j.1365-2265.2011.03969.x)
169. Stellato RK, Feldman HA, Hamdy O, Horton ES & McKinlay JB 2000 Testosterone, sex hormone binding globulin and the development of type 2 diabetes in middle aged men. Diabetes Care 23 490-494. (doi:10.2337/diacare.23.4.490)
170. Stratford S, Hoehn KL, Liu F & Summers SA 2004 Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. Journal of Biological Chemistry 279 36608-36615. (doi:10.1074/jbc.M406499200)
171. Stumvoll M, Jacob S, Wahl HG, Hauer B, Löblein K, Grauer P, Becker R, Nielsen M, Renn W & Häring H 2000 Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans. Journal of Clinical Endocrinology and Metabolism 85 3740-3745. (doi:10.1210/jc.85.10.3740)
172. Su CL, Huang HY, Shen ZQ & Lin JF 2009 The effects of testosterone on the expression of inflammatory factors in 3T3-L1 adipocytes and its mechanism. Zhonghua Yi Xue Za Zhi 89 1493-1497.
173. Svartberg J, Agledahl I, Figenschau Y, Sildnes T,Waterloo K & Jorde R 2008 Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. International Journal of Impotence Research 20 378-387. (doi:10.1038/ijir.2008.90)
174. Swinnen JV & Verhoeven G 1998 Androgens and the control of lipid metabolismin human prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology 65 191-908. (doi:10.1016/S0960-0760(97)00187-8)
175. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W & Verhoeven G 1996 Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137 4468-4474. (doi:10.1210/en.137.10.4468)
176. Swinnen JV, Ulrix W, HeynsW& Verhoeven G 1997 Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanisminvolving sterol regulatory element binding proteins. PNAS 94 12975-12980. (doi:10.1073/pnas.94.24.12975)
177. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA & Herbert PN 1989 Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. Journal of the American Medical Association 261 1165-1168. (doi:10.1001/jama.9089.03420080085036)
178. Traish AM, Guay A, Feeley R & Saad F 2009 The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. Journal of Andrology 30 10-22. (doi:10.2164/jandrol.108.005215)
179. Tsai EC, Boyko EJ, Leonetti DL & Fujimoto WY 2000 Low serum testosterone level as a predictor of increased visceral fat in Japanese- American men. International Journal of Obesity and Related Metabolic Disorders 24 485-491. (doi:10.1038/sj.ijo.0801183)
180. Uyanik BS, Ari Z, Gümüs B, Yigǐtoǧlu MR & Arslan T 1997 Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Japanese Heart Journal 38 73-82. (doi:10.1536/ihj.38.73)
181. Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G & Kaufman JM 2003 Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthymiddle-aged men. Atherosclerosis 166 95-102. (doi:10.1016/S0021-9150(02)00308-8)
182. Vikan T, Schirmer H, Njølstad I & Svartberg J 2009 Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. European Journal of Endocrinology 161 435-442. (doi:10.1530/EJE-09-0284)
183. VölzkeH, Aumann N, Krebs A, NauckM, Steveling A, Lerch MM,RosskopfD &Wallaschofski H 2010 Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. International Journal of Andrology 33 45-53. (doi:10.1111/j.1365-2605.2009.00953.x)
184. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N & Testosterone Gel Study Group 2000 Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 85 2839-2853. (doi:10.1210/jc.85.8.2839)
185. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M& Cunningham G 2011 Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk inmen with type 2 diabetes. Diabetes Care 34 1669-1675. (doi:10.2337/dc10-2339)
186. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA & Sowers JR 2007 Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 294 R673-R680. (doi:10.1152/ ajpregu.00561.2007)
187. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD & Siscovick DS 2001 Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. American Journal of Medicine 111 261-269. (doi:10.1016/S0002-9343(01)00833-6)
188. Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J & Bhasin S 2004 Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. Journal of Clinical Endocrinology and Metabolism 89 718-726. (doi:10.1210/jc.2003-031492)
189. Wu FC & von Eckardstein A 2003 Androgens and coronary artery disease. Endocrine Reviews 24 183-217. (doi:10.1210/er.2001-0025)
190. Xie P, Liu ML, Gu YP, Lu J, Xu X, Zeng WM & Song HP 2003 Oestrogen improves glucose metabolism and insulin signal transduction in HepG2 cells. Clinical and Experimental Pharmacology & Physiology 30 643-648. (doi:10.1046/j.1440-1681.2003.03899.x)
191. Yanase T, Fan W, Kyoya K, Min L, Takayanagi R, Kato S & Nawata H 2008 Androgens and metabolic syndrome: lessons from androgen receptor knock out (ARKO) mice. Journal of Steroid Biochemistry and Molecular Biology 109 254-257. (doi:10.1016/j.jsbmb.2008.03.017)
192. Yang Q, Graham TE,ModyN, Preitner F, Peroni OD, Zabolotny JM, KotaniK, Quadro L&KahnBB 2005 Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 356-362. (doi:10.1038/nature03711)
193. Yannucci J, Manola J, GarnickMB, Bhat G & Bubley GJ 2006 The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. Journal of Urology 176 520-525. (doi:10.1016/j.juro.2006.03.057)
194. Yassin AA, Saad F & Gooren LJ 2008 Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia 40 259-264. (doi:10.1111/j.1439-0272.2008.00851.x)
195. Yu YH & Ginsberg HN 2005 Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circulation Research 96 1042-1052. (doi:10.1161/01.RES.0000165803.47776.38)
196. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P, Chotkowska E, Srzednicki M & Sadowski Z 1996 Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121 35-43. (doi:10.1016/0021-9150(95)05673-4)
197. Zitzmann M 2009a Testosterone deficiency, insulin resistance and the metabolic syndrome. Nature Reviews. Endocrinology 5 673-681. (doi:10.1038/nrendo.2009.212)
198. Zitzmann M 2009b The role of the CAG repeat androgen receptor polymorphism in andrology. Frontiers of Hormone Research 37 52-61.
199. Zitzmann M & Nieschlag E 2007 Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 92 3844-3853. (doi:10.1210/jc.2007-0620)